Accéder au contenu
Merck
Toutes les photos(1)

Documents

SRP3026

Sigma-Aldrich

sDLL-4 human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture

Synonyme(s) :

Delta-like protein 4, Drosophila Delta homolog 4

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352200
Nomenclature NACRES :
NA.32

Source biologique

human

Produit recombinant

expressed in HEK 293 cells

Pureté

≥95% (HPLC)
≥95% (SDS-PAGE)

Forme

lyophilized

Puissance

>1.5 μg/mL (
)

Poids mol.

54.0 kDa

Conditionnement

pkg of 25 μg

Technique(s)

cell culture | mammalian: suitable

Impuretés

<0.1 EU/μg endotoxin, tested

Couleur

white

Numéro d'accès UniProt

Conditions d'expédition

wet ice

Température de stockage

−20°C

Informations sur le gène

human ... DLL4(54567)

Description générale

Human sDLL4 comprises the extracellular signaling domain of DLL, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. DLL4 functions to specifically activate the Notch-1 and Notch-4 receptors. The Notch signaling pathway regulates endothelial-cell differentiation, proliferation and apoptosis, and is essential for the development, maintenance and remodeling of the vascular system. Targeted deletion of the DLL4 gene in mice resulted in severe vascular defects and death before birth. Up-regulation of DLL4 expression has been implicated in the vascular development of certain tumors. Recombinant human sDLL4 is a 54.0 kDa glycoprotein containing 498 amino-acid residues. DLL4 is a membrane-bound notch ligand that belongs to the d protein family. Apart from the membrane-bound region, it consists of extracellular growth factor (EGF)-like domains and a receptor-binding DSL domain. DLL4 is selectively expressed in the endothelial cells and may act as a regulator of blood vessel biology.

Actions biochimiques/physiologiques

Human sDLL4 comprises the extracellular signaling domain of DLL, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. Recombinant human sDLL4 is a 54.0 kDa glycoprotein containing 498 amino-acid residues.

Séquence

SGVFQLQLQE FINERGVLAS GRPCEPGCRT FFRVCLKHFQ AVVSPGPCTF GTVSTPVLGT NSFAVRDDSS GGGRNPLQLP FNFTWPGTFS LIIEAWHAPG DDLRPEALPP DALISKIAIQ GSLAVGQNWL LDEQTSTLTR LRYSYRVICS DNYYGDNCSR LCKKRNDHFG HYVCQPDGNL SCLPGWTGEY CQQPICLSGC HEQNGYCSKP AECLCRPGWQ GRLCNECIPH NGCRHGTCST PWQCTCDEGW GGLFCDQDLN YCTHHSPCKN GATCSNSGQR SYTCTCRPGY TGVDCELELS ECDSNPCRNG GSCKDQEDGY HCLCPPGYYG LHCEHSTLSC ADSPCFNGGS CRERNQGANY ACECPPNFTG SNCEKKVDRC TSNPCANGGQ CLNRGPSRMC RCRPGFTGTY CELHVSDCAR NPCAHGGTCH DLENGLMCTC PAGFSGRRCE VRTSIDACAS SPCFNRATCY TDLSTDTFVC NCPYGFVGSR CEFPVGLP

Forme physique

Lyophilized from 1x PBS, pH 7.5.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development
Nicholas W
Proceedings of the National Academy of Sciences of the USA (2004)
Molecular cloning of delta-4, a new mouse and human Notch ligand
T Yoneya
Biochemistry, 129 (2001)
Minhong Yan et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(24), 7243-7246 (2007-12-21)
Intense research efforts have been focused toward the identification of regulators of angiogenesis and the development of antiangiogenesis-based cancer therapies. The approval of anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab) for use in colorectal and lung cancer provides clinical
Dll4, a novel Notch ligand expressed in arterial endothelium
J R Shutter
Genes & Development, 14 (2000)
G Thurston et al.
British journal of cancer, 99(8), 1204-1209 (2008-10-02)
Tumour angiogenesis has become an important target for antitumour therapy, with most current therapies aimed at blocking the VEGF pathway. However, not all tumours are responsive to VEGF blockers, and some tumours that are responsive initially may become resistant during

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique